Important Dates

Meeting dates: December 3-8, 2020

ASH News

Michelle M. Le Beau, PhD, Arthur and Marian Edelstein Professor of Medicine and director of the University of Chicago Medicine Comprehensive Cancer Center, will receive the 2020 Henry M. Stratton Medal from the American Society of Hematology (ASH) for her contributions to basic research. The medal, one of the cancer field’s top honors, recognizes investigators who have made well-recognized contributions to hematology research. Read the UCCCC article here, and the ASH announcement here.

Wendy Stock, MD, Anjuli Seth Nayak Professor of Medicine, will receive the 2020 Clinical Mentor Award for contributing to the professional development of numerous hematology trainees at various stages in her career. Read the ASH announcement here.

Jovian Yu, MD, second year fellow in the lab of Justin Kline, MD, was selected to receive an ASH Abstract Achievement Award for the submission: “Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8+ T Cell Population with a Cytotoxic Phenotype”.

Anand Patel, MD, fellow in the department of hematology/oncology, was selected to receive an ASH Abstract Achievement Award for the submission: “Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results”.

Sessions, Presentations, and Abstracts
(Note that bold names indicate UCCCC Members, and underlined means affiliated with University of Chicago; Ordered by session number)

Thursday, December 3, 2020

Blood Drop: Special Interest
Result Type: Session
Program: ASH–a–Palooza
#ASH20

**Presenter:** Lucy Godley  
**Time and Location:** Thursday, December 3, 2020: 7:15 AM–7:55 AM; 8:45 AM–9:25 AM

**Blood Buddies: Adult Clinical Malignant Hematology**  
**Result Type:** Session  
**Program:** ASH–a–Palooza  
**Presenter:** Olatoyosi Odenike  
**Time and Location:** Thursday, December 3, 2020: 10:00 AM–12:00 PM

**Germline Curation – Worked Examples**  
**Result Type:** Paper  
**Presenter:** Simone Feurstein  
**Program:** Scientific Workshops @ ASH  
**Session:** Variant Curation: How Should We Interpret What We Find?  
**Time and Location:** Thursday, December 3, 2020: 3:24 PM–4:19 PM

**Friday, December 4, 2020**

**Blood Drop: Hemostasis and Thrombosis**  
**Result Type:** Session  
**Program:** ASH–a–Palooza  
**Presenter:** Radhika Peddinti  
**Time and Location:** Friday, December 4, 2020: 7:15 AM–7:55 AM Channel 7; 8:45 AM–9:25 AM Channel 11

**Blood Buddies: Adult Clinical Malignant Hematology**  
**Result Type:** Session  
**Program:** ASH–a–Palooza  
**Presenter:** Wendy Stock  
**Time and Location:** Friday, December 4, 2020: 10:00 AM–12:00 PM

**Blood Buddies: Pediatric Clinical Malignant Hematology**  
**Result Type:** Session  
**Program:** ASH–a–Palooza  
**Presenter:** Tara Henderson  
**Time and Location:** Friday, December 4, 2020: 10:00 AM–12:00 PM

**Blood Buddies: Pediatric Clinical Malignant Hematology**  
**Result Type:** Session  
**Program:** ASH–a–Palooza  
**Presenter:** Jennifer McNeer  
**Time and Location:** Friday, December 4, 2020: 10:00 AM–12:00 PM
Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman–Diamond Syndrome

Result Type: Paper
Number: 254
Presenter: Alyssa Kennedy
A Kennedy…Wendy Stock…C Lindsley.
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders
Time and Location: Saturday, December 5, 2020: 2:00 PM–3:30 PM; Channel 18

RNA Cytosine Methyltransferases NSUN1 and NSUN2 Mediate the Lineage–Associated Resistance to Venetoclax in Leukemia

Result Type: Paper
Number: 964
Presenter: Shaun Wood
S Wood…Jason Cheng.
Program: Oral and Poster Abstracts
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
Time and Location: Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

Preliminary Results of Balli–01: A Phase I Study of UCART22 (allogeneic engineered T–cells expressing anti–CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B–Cell Acute Lymphoblastic Leukemia (B–ALL)

Result Type: Paper
Number: 163
Presenter: Nitin Jain
N Jain…Hongtao Liu…Richard Larson.
Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy
Time and Location: Saturday, December 5, 2020: 12:00 PM–1:30 PM; Channel 13

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Result Type: Paper
Number: 1149
Presenter: Nathan Fowler
N Fowler…Peter Riedell…C Thieblemont.
Program: Oral and Poster Abstracts
#ASH20

**Session:** 623. Mantle Cell, Follicular, and Other Indolent B–Cell Lymphoma—Clinical Studies: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**A Phase I Study of Anti–ICOS Antibody MEDI–570 for Relapsed/Refractory (R/R) Peripheral T–Cell Lymphoma (PTCL) and Angioimmunoblastic T–Cell Lymphoma (AITL) (NCI–9930)**

**Result Type:** Paper

**Number:** 1151

**Presenter:** Julio Chavez

J Chavez...Sonali Smith...L Siu.

**Program:** Oral and Poster Abstracts

**Session:** 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

**Time and Location:**
Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B–Cell Lymphoma (DLBCL): A Post–Hoc Analysis of the Sadal Pivotal Study**

**Result Type:** Paper

**Number:** 1201

**Presenter:** Marie Maerevoet

M Schuster...Sonali Smith...M Maerevoet.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B–Cell and Other Aggressive B–Cell Non–Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas**

**Result Type:** Paper

**Number:** 1189

**Presenter:** Ajay Major

Ajay Major, Justin Kline, Theodore Karrison...Sonali Smith.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B–Cell and Other Aggressive B–Cell Non–Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**Myc Expression and Tumor–Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B–Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial**

**Result Type:** Paper

**Number:** 1194

**Presenter:** Ulrich Jaeger
#ASH20

U Jaeger, Michael Bishop...P Corradini.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B–Cell and Other Aggressive B–Cell Non–Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor**

**Result Type:** Paper

**Number:** 53

**Presenter:** John Mascarenhas

J Mascarenhas...Olatoyosi Odenike...J Kiladijian.

**Program:** Oral and Poster Abstracts

**Session:** 634. Myeloproliferative Syndromes: Clinical: New Therapies and JAKi–based Combinations for Myelofibrosis

**Time and Location:** Saturday, December 5, 2020: 7:30 AM–9:00 AM; Channel 15

**Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)**

**Result Type:** Paper

**Number:** 1230

**Presenter:** Michael Savona

M Savona...Olatoyosi Odenike...G Garcia–Manero.

**Program:** Oral and Poster Abstracts

**Session:** 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher–Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study**

**Result Type:** Paper

**Number:** 1283

**Presenter:** John Mascarenhas

J Mascarenhas...Olatoyosi Odenike...J Kiladijan

**Program:** Oral and Poster Abstracts

**Session:** 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B–Cell Lymphoma (DLBCL): A Post–Hoc Analysis from the Pivotal Phase 2b Sadal Study**

**Result Type:** Paper

**Number:** 1384

**Presenter:** Jason Westin
Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Result Type: Paper
Number: 1412
Presenter: Adam Cohen
A Cohen...Andrzej Jakubowiak, S Jagannath.
Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
Time and Location: Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Result Type: Paper
Number: 1397
Presenter: Jagoda Jasielec
J Jasielec...Benjamin Derman...Andrzej Jakubowiak.
Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
Time and Location: Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Result Type: Paper
Number: 130
Presenter: Melissa Alsina
M Alsina...Andrzej Jakubowiak...J Berdeja.
Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data
Time and Location: Saturday, December 5, 2020: 9:30 AM–11:00 AM; Channel 10

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Result Type: Paper
Number: 177
Presenter: Deepu Madduri
D Madduri...Andrzej Jakubowiak...T Martin.
Program: Oral and Poster Abstracts
#ASH20

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma  
**Time and Location:** Saturday, December 5, 2020: 12:00 PM–1:30 PM; Channel 10

**Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine–Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo–SCT)**  
**Result Type:** Paper  
**Number:** 191  
**Presenter:** Hongtao Liu  
Hongtao Liu, Bulent Aydogan…Amy Wang…Wendy Stock, Richard Larson..James LaBelle, Justin Kline, Peter Riedell…Michael Bishop.  
**Program:** Oral and Poster Abstracts  
**Session:** 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities II  
**Time and Location:** Saturday, December 5, 2020: 12:00 PM–1:30 PM; Channel 23

**Barriers and Resident Attitudes Surrounding Care of Patients with Sickle Cell Disease**  
**Result Type:** Paper  
**Number:** 1569  
**Presenter:** Daniela Anderson  
**Program:** Oral and Poster Abstracts  
**Session:** 901. Health Services Research—Non–Malignant Conditions: Poster I  
**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**Real–World Validity of the Revised International Staging System in Multiple Myeloma By Race**  
**Result Type:** Paper  
**Number:** 1641  
**Presenter:** Lucia Notardonato  
L Notardonato…Brian Chiu, Benjamin Derman.  
**Program:** Oral and Poster Abstracts  
**Session:** 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I  
**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

**The Role of Structural Violence in Acute Myeloid Leukemia Outcomes**  
**Result Type:** Paper  
**Number:** 217  
**Presenter:** Irum Khan  
I Abraham…Anand Patel…I Khan.  
**Program:** Oral and Poster Abstracts  
**Session:** 906—Outcomes Research—Malignant Conditions (Myeloid Disease): Real World Management
**Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms**

*Result Type:* Paper  
*Number:* 1  
*Presenter:* Christian Marinaccio  
*C Marinaccio...Sandeep Gurbuxani...J Crispino.*  
*Program:* General Sessions  
*Session:* Plenary Scientific Session  
*Time and Location:* Sunday, December 6, 2020: 7:00 AM–9:00 AM; Channel 1

**Thromboelastography in Evaluation of Hyperfibrinolysis: A Single Center Review**

*Result Type:* Paper  
*Number:* 1792  
*Presenter:* Timothy Carll  
*Carll, Geoffrey Wool.*  
*Program:* Oral and Poster Abstracts  
*Session:* 322. Disorders of Coagulation or Fibrinolysis: Poster II  
*Time and Location:* Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

**D–Dimer As a Predictor of Thrombotic Events during Early Acute Lymphoblastic Leukemia Therapy**

*Result Type:* Paper  
*Number:* 1901  
*Presenter:* Daniela Anderson  
*Anderson...Theodore Karrison, Wendy Stock.*  
*Program:* Oral and Poster Abstracts  
*Session:* 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II  
*Time and Location:* Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

**Therapy–Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only**

*Result Type:* Paper  
*Number:* 1920  
*Presenter:* Anand Patel  
*Anand Patel...Michael Drazer, Lucy Godley, Michelle Le Beau, Richard Larson.*  
*Program:* Oral and Poster Abstracts  
*Session:* 613. Acute Myeloid Leukemia: Clinical Studies: Poster II  
*Time and Location:* Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell–Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

**Result Type:** Paper

**Number:** 460

**Presenter:** Farhad Ravandi, Wendy Stock, and Mims.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies

**Time and Location:** Sunday, December 6, 2020: 2:00 PM–3:30 PM; Channel 12

---

Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603)

**Result Type:** Paper

**Number:** 391

**Presenter:** Frank Rücker, Richard Larson, and K. Dohner.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Molecular Mutations and Their Prognostic Implications

**Time and Location:** Sunday, December 6, 2020: 12:00 PM–1:30 PM; Channel 12

---

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

**Result Type:** Paper

**Number:** 1904

**Presenter:** Marina Konopleva, Michael Thirman, and A. Wei.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

---

The First-in-Class Anti–CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results

**Result Type:** Paper

**Number:** 330

**Presenter:** David Sallman, Richard Larson, and N. Daver.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches

**Time and Location:** Sunday, December 6, 2020: 9:30 AM–11:00 AM; Channel 12

---

R-CHOP Versus R–Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET
Survival Varies By Age and Histology in Classical Hodgkin Lymphoma: A Report from the Children’s Oncology Group

Macrophage Activation By Dual PI3K–δ/γ Inhibition Enhances Anti–CD47–Mediated Phagocytosis and Prolongs Survival in DLBCL

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients
Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat

**Result Type:** Paper
**Number:** 347
**Presenter:** John Mascarenhas
J Mascarenhas...Olatoyosi Odenike...J Kiladjian.
**Program:** Oral and Poster Abstracts
**Session:** 634. Myeloproliferative Syndromes: Clinical: Translational Science in MPN—Hitting the Mark
**Time and Location:** Sunday, December 6, 2020: 9:30 AM–11:00 AM; Channel 15

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose–Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

**Result Type:** Paper
**Number:** 2251
**Presenter:** Luciano Costa
L Costa...Andrzej Jakubowiak...F Davies.
**Program:** Oral and Poster Abstracts
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant–Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab–Based Regimens: Analysis of Maia and Alcyone

**Result Type:** Paper
**Number:** 2317
**Presenter:** Jesus San–Miguel
J San–Miguel...Andrzej Jakubowiak...N Bahlis.
**Program:** Oral and Poster Abstracts
**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

Health–Related Quality of Life in the Cartitude–1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

**Result Type:** Paper
**Number:** 2291
**Presenter:** Thomas Martin
T Martin...Andrzej Jakubowiak, S Jagannath.
**Program:** Oral and Poster Abstracts
**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

**Result Type:** Paper  
**Number:** 2285  
**Presenter:** Shaji Kumar  
S Kumar...**Andrzej Jakubowiak**...B Durie.  
**Program:** Oral and Poster Abstracts  
**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II  
**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

Creating a Variant Database for the American Society of Hematology By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

**Result Type:** Paper  
**Number:** 360  
**Presenter:** Niroshan Nadarajah  
N Nadarajah...**Michelle Le Beau**...T Haferiach.  
**Program:** Oral and Poster Abstracts  
**Session:** 803. Emerging Diagnostic Tools and Techniques I  
**Time and Location:** Sunday, December 6, 2020: 9:30 AM–11:00 AM; Channel 21

Identifying Potential Drug Targets for Sickle Cell Disease through Gene Expression and Pathway Analysis of GEO Data

**Result Type:** Paper  
**Number:** 2617  
**Presenter:** Sharjeel Syed  
Sharjeel Syed...D Hadley.  
**Program:** Oral and Poster Abstracts  
**Session:** 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III  
**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

Transcriptional Control of HP1a By the RNA Binding Proteins RbmX/L1 Maintain Chromatin State in Myeloid Leukemia

**Result Type:** Paper  
**Number:** 523  
**Presenter:** Diu Nguyen  
D Nguyen...**Katerina Hoskova**, Meera Dhodapkar...M Kharas.  
**Program:** Oral and Poster Abstracts  
**Session:** 603. Oncogenes and Tumor suppressors: Pre–clinical models and Novel Targets  
**Time and Location:** December 7, 2020: 7:00 AM–8:30 AM; Channel 14 (Virtual Meeting)
Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Result Type: Paper
Number: 2796
Presenter: Anand Patel
Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8+ T Cell Population with a Cytotoxic Phenotype

Result Type: Paper
Number: 594
Presenter: Jovian Yu
James Godfrey, Sonali Smith, Justin Kline.
Program: Oral and Poster Abstracts
Session: 622. Lymphoma Biology—Non-Genetic Studies: Microenvironment and Immune Response in Hodgkin Lymphoma
Time and Location: Monday, December 7, 2020: 9:00 AM–10:30 AM; Channel 8

Molecular Characteristics and Patterns of Progression of IDH2-Mutated, Philadelphia-Chromosome Negative, Advanced-Phase Myeloproliferative Neoplasms Treated with Enasidenib

Result Type: Paper
Number: 2999
Presenter: Anand Patel
Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Result Type: Paper
Number: 3051
Presenter: Prashasti Agrawal
P Agrawal, Sonali Smith, P Martin.
Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)
Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Result Type: Paper
Number: 546
Presenter: Tanya Siddiqi
T Siddiqi…Peter Riedell…W Wierda.
Program: Oral and Poster Abstracts
Session: 642. CLL: Therapy, excluding Transplantation II
Time and Location: Monday, December 7, 2020: 7:00 AM–8:30 AM; Channel 9 (Virtual Meeting)

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Result Type: Paper
Number: 3109
Presenter: Amer Zeidan
A Zeidan…Olatoyosi Odenike…G Garcia–Manero.
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study

Result Type: Paper
Number: 3240
Presenter: Yi Lin
Y Lin…Andrzej Jakubowiak…S Jagannath.
Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Result Type: Paper
Number: 549
Presenter: Jonathan Kaufman
J Kaufman…Andrzej Jakubowiak…P Voorhees.
Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy
Time and Location: Monday, December 7, 2020: 7:00 AM–8:30 AM; Channel 10 (Virtual Meeting)
Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

**Result Type:** Paper  
**Number:** 3224  
**Presenter:** Sagar Lonial  
S Lonial...Andrzej Jakubowiak.  
**Program:** Oral and Poster Abstracts  
**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III  
**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

**Result Type:** Paper  
**Number:** 2953  
**Presenter:** Yazeed Sawalha  
Y Sawalha...Peter Riedell...J Cohen.  
**Program:** Oral and Poster Abstracts  
**Session:** 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III  
**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

**Result Type:** Paper  
**Number:** 704  
**Presenter:** Samuel Yamshon  
S Yamshon...Sonali Smith...J Ruan.  
**Program:** Oral and Poster Abstracts  
**Session:** 623. Mantle Cell and Indolent B-Cell Lymphoma – CAR-T and immunotherapy clinical studies  
**Time and Location:** Monday, December 7, 2020: 1:30 PM–3:00 PM; Channel 7 (Virtual Meeting)

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

**Result Type:** Paper  
**Number:** 636  
**Presenter:** Eytan Stein  
E Stein...Wendy Stock...A Mims.  
**Program:** Oral and Poster Abstracts  
**Session:** 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation II  
**Time and Location:** Monday, December 7, 2020: 11:30 AM–1:00 PM; Channel 12 (Virtual Meeting)
Combined Inhibition of CXCR4 Signaling and System x- Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis

Result Type: Paper
Number: 695
Presenter: Jun Xia
J Xia…Matthew Jotte…D Link.
Program: Oral and Poster Abstracts
Session: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I
Time and Location: Monday, December 7, 2020: 1:30 PM–3:00 PM; Channel 13 (Virtual Meeting)

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Result Type: Paper
Number: 2969
Presenter: Alex Herrera
A Herrera…Sonali Smith, J Friedberg.
Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall

Treatment with Imetelstat Improves Myelofibrosis–Related Symptoms and Other Patient–Reported Outcomes in Patients with Relapsed or Refractory Higher–Risk Myelofibrosis

Result Type: Paper
Number: 3088
Presenter: Jean-Jacques Kiladjian
J Kiladjian…Olatoyosi Odenike…A Vannucchi.
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall

Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher–Risk Triple–Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi)

Result Type: Paper
Number: 3084
Presenter: Jean-Jacques Kiladjian
J Kiladjian…Olatoyosi Odenike…A Vannucchi.
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall

Safety, Efficacy, and Patient–Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher–Risk Myelodysplastic Syndrome: A Phase 1b Study
#ASH20

**Result Type:** Paper  
**Number:** 656  
**Presenter:** Jacqueline Garcia
J Garcia...Olatoyosi Odenike...G Garcia–Manero.  
**Program:** Oral and Poster Abstracts  
**Session:** 637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk  
Myelodysplastic syndromes  
**Time and Location:** Monday, December 7, 2020: 11:30 AM–1:00 PM; Channel 15 (Virtual Meeting)

**Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma**  
**Result Type:** Paper  
**Number:** 3199  
**Presenter:** Matthew Frigault
M Frigault, Michael Bishop...M Maus.  
**Program:** Oral and Poster Abstracts  
**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III  
**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

**Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)–CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)**  
**Result Type:** Paper  
**Number:** 3206  
**Presenter:** Alexander Lesokhin
A Lesokhin...Andrzej Jakubowiak...N Raje.  
**Program:** Oral and Poster Abstracts  
**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III  
**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

**Assessing the Feasibility and Limitations of Cultured Skin Fibroblasts for Germline Genetic Testing in Hematologic Disorders**  
**Result Type:** Paper  
**Number:** 3385  
**Presenter:** Lia DeRoin
Lia DeRoin...Lucy Godley, Jeremy Segal...J Churpek.  
**Program:** Oral and Poster Abstracts  
**Session:** 803. Emerging Diagnostic Tools and Techniques: Poster III  
**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

**Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG–ACRIN Cancer Research Group (E1A141)**
Result Type: Paper
Number: 3380
Presenter: Ryan Mattison, R. Jeraj, Daniel Arber, D. Mankoff.
Program: Oral and Poster Abstracts
Session: 803. Emerging Diagnostic Tools and Techniques: Poster III
Time and Location: Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)